{"id":"NCT04940390","sponsor":"Satsuma Pharmaceuticals, Inc.","briefTitle":"A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine","officialTitle":"A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-30","primaryCompletion":"2022-10-13","completion":"2022-10-26","firstPosted":"2021-06-25","resultsPosted":"2023-07-24","lastUpdate":"2023-11-27"},"enrollment":1591,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine","Migraine With Aura","Migraine Without Aura"],"interventions":[{"type":"DRUG","name":"Dihydroergotamine","otherNames":["Dihydroergotamine Mesylate"]},{"type":"DRUG","name":"Placebo","otherNames":["STS101 Placebo"]}],"arms":[{"label":"STS101","type":"EXPERIMENTAL"},{"label":"STS101 Placebo","type":"EXPERIMENTAL"}],"summary":"Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.","primaryOutcome":{"measure":"Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose","timeFrame":"2 Hours Post-Dose","effectByArm":[{"arm":"STS101 5.2 mg","deltaMin":146,"sd":null},{"arm":"STS101 Placebo","deltaMin":124,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":127,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":731},"commonTop":["Nasal Discomfort","Dysgeusia","Nasal Congestion"]}}